BloggingStocks http://www.bloggingstocks.com BloggingStocks http://www.blogsmithmedia.com/http://www.bloggingstocks.com/media/feedlogo.gif BloggingStocks http://www.bloggingstocks.com en-us Copyright 2012 Weblogs, Inc. The contents of this feed are available for non-commercial use only. Blogsmith http://www.blogsmith.com/<![CDATA[Celgene Remains in an Uptrend]]>http://www.bloggingstocks.com/2009/12/21/celgene-remains-in-an-uptrend/http://www.bloggingstocks.com/2009/12/21/celgene-remains-in-an-uptrend/http://www.bloggingstocks.com/2009/12/21/celgene-remains-in-an-uptrend/#commentsFiled under:

Celgene Corp.'s (CELG) stock has encountered resistance at $58, but I'm nevertheless reiterating my buy rating for the company's shares, first recommended on June 19, 2009, at a price of $46.94. Here's why:

Look for Celgene's FY2010 revenue to increase 20-23%, on top of a likely a 15-20% rise in FY2009, boosted by cancer treatments Revlimid's and Vidaza's sales. Further, pipeline candidates to treat psoriasis and small cell lung cancer are approaching late-stage study.

Continue reading Celgene Remains in an Uptrend

Celgene Remains in an Uptrend originally appeared on BloggingStocks on Mon, 21 Dec 2009 17:00:00 EST. Please see our terms for use of feeds.

Permalink | Email this | Comments]]>cancercelgCelgene Corp.psoriasisrevlimidvidazaMon, 21 Dec 2009 17:00:00 EST<![CDATA[Time to scoop up some shares of Celgene]]>http://www.bloggingstocks.com/2009/06/19/time-to-scoop-up-some-shares-of-celgene/http://www.bloggingstocks.com/2009/06/19/time-to-scoop-up-some-shares-of-celgene/http://www.bloggingstocks.com/2009/06/19/time-to-scoop-up-some-shares-of-celgene/#commentsFiled under:

Pharmaceutical company Celgene Corp., beaten down by Wall Street for the better part of 10 months, is now a Buy in these circles. Here's why:

Analysts now expect FY2009 revenue to increase 15-18%, boosted by Revlimid and Vidaza sales. Further, pipeline candidates in psoriasis and small cell lung cancer are nearing late-stage study. The First Call FY2009/FY2010 EPS estimates for CELG are $2.04 to $2.65.

Continue reading Time to scoop up some shares of Celgene

Time to scoop up some shares of Celgene originally appeared on BloggingStocks on Fri, 19 Jun 2009 17:00:00 EST. Please see our terms for use of feeds.

Permalink | Email this | Comments]]>CELGCelgenerevlimidvidazaFri, 19 Jun 2009 17:00:00 EST<![CDATA[Major mover: Pharmion (PHRM) jumps by half]]>http://www.bloggingstocks.com/2007/08/02/major-mover-pharmion-phrm/http://www.bloggingstocks.com/2007/08/02/major-mover-pharmion-phrm/http://www.bloggingstocks.com/2007/08/02/major-mover-pharmion-phrm/#commentsFiled under:

Positive test results for Pharmion Corporation (NASDAQ: PHRM)'s drug Vidaza shot the global pharmaceutical firm's shares more than 50% higher in morning trading Thursday. Pharmion is currently the biggest percentage gainer on the NASDAQ.

Vidaza is said to significantly extend the life of patients with myelodysplastic syndrome. In a late-stage study, results showed that taking Vidaza extends the median survival of 15 months for those on conventional treatments to 24.4 months. Shortly before 1:30 p.m., Pharmion shares were trading at $37.60, up 52% from Wednesday's $24.64 close.

Major mover: Pharmion (PHRM) jumps by half originally appeared on BloggingStocks on Thu, 02 Aug 2007 13:27:00 EST. Please see our terms for use of feeds.

Permalink | Email this | Comments]]>major movementMajorMovementmyelodysplastic syndromeMyelodysplasticSyndromePharmionPHRMtop gainersTopGainersVidazaThu, 02 Aug 2007 13:27:00 EST